AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
Highlights
- RC220 and doxorubicin combination enters Phase 1
- No serious toxicities seen in initial patient
- Expansion planned into Asia, US, and Europe
Race Oncology (ASX:RAC) has marked a pivotal moment in its drug development journey with the successful dosing of the first patient in its Phase 1 clinical trial of RC220 in combination with doxorubicin. This open-label trial, aimed at addressing the cardiac toxicity commonly associated with doxorubicin, is an important step forward for both cancer treatment innovation and the company’s broader international ambitions.
Doxorubicin is widely recognised for its effectiveness in treating various solid tumours. However, its well-documented side effect—damage to the heart—often limits its prolonged use. Race Oncology’s novel candidate, RC220, is being tested as a companion therapy designed to mitigate this cardiovascular risk. According to Dr. Simon Fisher, Vice President of Medical at Race Oncology, the dual therapy may slow or even prevent the progression of cardiac damage when used in tandem with doxorubicin.
The trial’s first patient experienced no dose-limiting toxicities, an encouraging signal for the safety profile of RC220. Dr. Fisher confirmed that there were no events requiring discontinuation of treatment, which is particularly significant for a Phase 1 study that primarily assesses safety over extended use.
Beyond clinical safety, this study positions Race Oncology on a global path. The trial is not limited to Australia—regulatory submissions are in progress for Hong Kong and South Korea, with site activations expected shortly. The company also plans to expand into the United States and Europe, underscoring its commitment to making the therapy globally accessible.
Race Oncology’s advancement comes at a time when investor interest in biotech is being closely watched within the context of broader market benchmarks like the ASX200. With a growing number of healthcare and biotech firms seeking a spot in this index, Race Oncology’s proactive development strategy and international aspirations could contribute meaningfully to its future trajectory.
The company remains focused on validating the long-term safety and effectiveness of RC220. If successful, the treatment could offer oncologists a much-needed option to extend doxorubicin use without compromising cardiac health—benefiting both patients and the evolving cancer care landscape.
